Literature DB >> 23931489

Dexamethasone implant for the treatment of edema related to idiopathic macular telangiectasia.

Otman Sandali, Jad Akesbi, Thibaut Rodallec, Laurent Laroche, Jean-Philippe Nordmann.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23931489     DOI: 10.1016/j.jcjo.2013.01.022

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


× No keyword cloud information.
  5 in total

1.  Macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex).

Authors:  Mohamed Loutfi; Thomas Papathomas; Ahmed Kamal
Journal:  Case Rep Ophthalmol Med       Date:  2014-06-17

2.  CLINICAL FEATURES OF TREATED AND UNTREATED TYPE 1 IDIOPATHIC MACULAR TELANGIECTASIA WITHOUT THE OCCURRENCE OF SECONDARY CHOROIDAL NEOVASCULARIZATION FOLLOWED FOR 2 YEARS IN JAPANESE PATIENTS.

Authors:  Rie Osaka; Chieko Shiragami; Aoi Ono; Mamoru Kobayashi; Yukari Takasago; Ayana Yamashita; Akitaka Tsujikawa
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

3.  Multimodal Imaging Findings and Treatment with Dexamethasone Implant in Three Cases of Idiopathic Macular Telangiectasia Type 1.

Authors:  Paola Cirafici; Maria Musolino; Michela Saccheggiani; Carlo Enrico Traverso; Massimo Nicolò
Journal:  Case Rep Ophthalmol       Date:  2021-04-06

Review 4.  Widening use of dexamethasone implant for the treatment of macular edema.

Authors:  Vincenza Bonfiglio; Michele Reibaldi; Matteo Fallico; Andrea Russo; Alessandra Pizzo; Stefano Fichera; Carlo Rapisarda; Iacopo Macchi; Teresio Avitabile; Antonio Longo
Journal:  Drug Des Devel Ther       Date:  2017-08-16       Impact factor: 4.162

Review 5.  Local delivery of corticosteroids in clinical ophthalmology: A review.

Authors:  Adrian T Fung; Tuan Tran; Lyndell L Lim; Chameen Samarawickrama; Jennifer Arnold; Mark Gillies; Caroline Catt; Logan Mitchell; Andrew Symons; Robert Buttery; Lisa Cottee; Krishna Tumuluri; Paul Beaumont
Journal:  Clin Exp Ophthalmol       Date:  2020-01-22       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.